Agilent Technologies’ (A) Buy Rating Reiterated at Robert W. Baird

Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reaffirmed by analysts at Robert W. Baird in a research note issued on Thursday. They presently have a $76.00 target price on the medical research company’s stock. Robert W. Baird’s price objective would suggest a potential upside of 5.28% from the company’s previous close.

A number of other brokerages also recently weighed in on A. Barclays raised their price objective on Agilent Technologies from $67.00 to $71.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. JPMorgan Chase & Co. raised their price objective on Agilent Technologies to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Deutsche Bank set a $75.00 price objective on Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. Cowen reissued a “hold” rating and issued a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Finally, ValuEngine downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $69.25.

Agilent Technologies (NYSE:A) traded up $0.13 on Thursday, hitting $72.19. The stock had a trading volume of 1,782,821 shares, compared to its average volume of 1,800,000. Agilent Technologies has a 52 week low of $47.05 and a 52 week high of $72.50. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. The stock has a market cap of $23,230.00, a P/E ratio of 34.54, a PEG ratio of 2.15 and a beta of 1.28.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business earned $0.59 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. equities analysts forecast that Agilent Technologies will post 2.58 earnings per share for the current year.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 43,703 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $70.00, for a total value of $3,059,210.00. Following the sale, the chief executive officer now owns 302,837 shares of the company’s stock, valued at approximately $21,198,590. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Doak sold 15,567 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $68.00, for a total value of $1,058,556.00. Following the completion of the sale, the insider now directly owns 71,104 shares in the company, valued at approximately $4,835,072. The disclosure for this sale can be found here. Insiders sold a total of 176,291 shares of company stock worth $12,245,920 in the last ninety days.

Several large investors have recently made changes to their positions in the company. Syntal Capital Partners LLC grew its holdings in shares of Agilent Technologies by 65.7% during the 4th quarter. Syntal Capital Partners LLC now owns 12,385 shares of the medical research company’s stock worth $829,000 after purchasing an additional 4,912 shares in the last quarter. Coastline Trust Co grew its holdings in shares of Agilent Technologies by 140.2% during the 4th quarter. Coastline Trust Co now owns 24,695 shares of the medical research company’s stock worth $1,654,000 after purchasing an additional 14,415 shares in the last quarter. Creative Planning grew its holdings in shares of Agilent Technologies by 11.0% during the 4th quarter. Creative Planning now owns 17,113 shares of the medical research company’s stock worth $1,146,000 after purchasing an additional 1,698 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Agilent Technologies by 187.3% during the 4th quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after purchasing an additional 483,721 shares in the last quarter. Finally, New England Research & Management Inc. grew its holdings in shares of Agilent Technologies by 79.2% during the 4th quarter. New England Research & Management Inc. now owns 11,650 shares of the medical research company’s stock worth $780,000 after purchasing an additional 5,150 shares in the last quarter.

WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/19/agilent-technologies-a-buy-rating-reiterated-at-robert-w-baird.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply